Core Insights - NewGen plans to invest US$45 million in the UAE real estate market, focusing on properties near the Wynn Al Marjan Island integrated resort, marking a diversification from its traditional IVF business operations [1][2] - The investment is driven by Ras Al Khaimah's strong economic growth, political stability, and significant infrastructure developments, which are expected to enhance property values [2][5] - NewGen is also considering additional investments in Abu Dhabi's real estate market, which offers stability and long-term growth potential [2][3] Investment Strategy - The company has engaged UAE-based business development manager Samira Aissani to lead property acquisition initiatives, leveraging her extensive experience in UAE real estate [3] - NewGen is in advanced discussions for strategic plot acquisitions in Ras Al Khaimah and has established partnerships with prominent UAE developers [3][4] - A term sheet has been executed with Enclave Capital LLC to raise an additional US$45 million to support the UAE real estate expansion [4] Market Potential - The Wynn Al Marjan Island integrated resort, a multi-billion dollar development set to open in early 2027, is expected to drive demand for real estate in Ras Al Khaimah [2] - The region's strategic location, with 31% of the world's population within four hours' flying time, along with favorable investment policies, creates an ideal environment for real estate appreciation [2] - NewGen's CEO expressed confidence that the investment will deliver substantial returns and establish a strong foundation for future growth [5]

SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29 ...

Core Insights - NewGenIvf Group Limited has launched First Fertility PGS Center Limited to target the Indian medical tourism market for fertility treatments [1][2] - The global fertility tourism market is projected to grow from US$709 million in 2023 to approximately US$13.08 billion by 2034, with a compound annual growth rate of 30.34% [2] - Thailand is becoming a preferred destination for fertility tourism due to its advanced medical infrastructure, cost-effective treatments, and supportive regulatory environment [2][4] Company Initiatives - First Fertility has developed culturally tailored services for Indian patients, including a dedicated hospitality lounge and Hindi-speaking staff [3] - The center offers comprehensive fertility treatments, including family balance through IVF, which is restricted in India but legally available in Thailand [3] - The initiative aims to create a culturally sensitive environment while providing access to advanced reproductive technologies [3] Market Positioning - Thailand's strategic advantages, such as visa-free entry for Indian nationals and a progressive regulatory environment, support the growth of the medical tourism sector [4] - First Fertility addresses the gap in culturally tailored fertility care for Indian patients, who represent a significant segment of the medical tourism market [4] - The CEO of NewGen emphasized the company's commitment to providing world-class fertility care while capitalizing on market opportunities in Southeast Asia [5]

Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya TherapeuticsSARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced first quarter 2025 fi ...

Financial Data and Key Metrics Changes - First quarter revenue grew 16.5% to $324 million, primarily due to an increase in the number of clients and covered lives compared to the previous year [15] - Adjusted EBITDA increased by 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [22][28] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [22] Business Line Data and Key Metrics Changes - Fertility revenue increased 22% to $206 million, while pharmacy revenue grew 9% to $118 million [20] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [19] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 continue to rise, indicating a shift in family planning trends [6][7] - Over 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity solutions [8] Company Strategy and Development Direction - The company is focusing on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [5][9] - New services in maternity, postpartum, and menopause are expected to contribute up to 10% of revenue by 2028, although significant contributions are not anticipated in the near term [13][14] Management's Comments on Operating Environment and Future Outlook - Management raised full-year guidance, projecting revenue between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [27] - The company expects continued member engagement at historical levels, despite potential variability in activity and treatments [25] Other Important Information - The company generated nearly $50 million in operating cash flow in the first quarter, nearly double the prior year period [23] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [24] Q&A Session Summary Question: Historical seasonality of cycles per utilizer - Management indicated that guidance reflects uncertainty rather than a change in normal seasonality [30] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and while they expect gross margin expansion for the full year, investments may impact margins [31][33] Question: 2026 selling season and RFP process - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [38][43] Question: Incremental adjusted EBITDA margin - Management explained that the lower margin is due to investments in platform and product expansion, which are expected to impact the P&L this year [44] Question: Interest in new modules - The menopause product is seeing higher engagement due to a larger addressable audience compared to maternity products [47] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and potential tariffs on pharmaceuticals are not expected to affect their operations [53] Question: Pricing benefits in ART cycles - Management clarified that growth is driven by engagement and activity rather than pricing [68]

Core Insights - NewGen has rebranded its MicroSort technology to NewGenSort, integrating it into its product offerings to enhance reproductive solutions in Asia [1][4] - NewGenSort technology allows for the separation of X and Y chromosome-bearing sperm cells, facilitating family planning and prevention of genetic diseases [2][3] Company Overview - NewGenIvf Group Limited is a comprehensive fertility services provider in Asia, offering a range of fertility treatments to couples and individuals [5] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as infertility treatments, egg and sperm donation, and surrogacy [5] Technology Applications - NewGen plans to utilize its sperm-sorting technology through two applications: MicroSort for gender selection and MacroSort for addressing male reproductive challenges [3] - MicroSort enables couples to balance family composition, while MacroSort focuses on avoiding sex-linked genetic disorders [3] Strategic Vision - The integration of NewGenSort is seen as a pivotal advancement for the company, expected to accelerate growth and expand market share across Asia [4] - The technology aims to provide personalized reproductive solutions, enhancing the overall family health and prosperity for clients [4]

SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results. Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted) Revenue was $1,685,966, an increase of 22% compared to $1,381,754.Con ...

Core Viewpoint - NewGenIvf Group Limited has filed its annual report for the fiscal year ended December 31, 2024, indicating a strong liquidity position and strategic opportunities in the fertility services market in Asia [1][2]. Company Overview - NewGen is a comprehensive fertility services provider in Asia, dedicated to helping couples and individuals access fertility treatments [3]. - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of services including infertility treatments, egg and sperm donation, and surrogacy [3]. - The management team has over a decade of experience in the fertility industry [3]. Financial Position - The company reported having $2.48 million in cash and a cash deposit of $1 million, significantly exceeding its current market capitalization of $1.48 million [2]. - NewGen has strengthened its balance sheet by settling all outstanding promissory notes and converting several mandatory additional notes into equity [2]. - The company has access to a $100 million equity line of credit facility, with approximately $7.1 million drawn to date, positioning it well for future strategic opportunities [2].

Core Points - The Wyatt Foundation and The Conceive Fertility Foundation launched a 2025 IVF grant program during National Infertility Awareness Week, offering $15,000 grants to five individuals or couples needing fertility care [1][6] - CooperSurgical is participating for the first time, providing an additional $1,000 for preimplantation genetic testing (PGT) for each grant recipient [2][3] - The program aims to raise awareness about infertility, alleviate financial burdens, and support research for more affordable fertility care options [1][4] Company Overview - The Wyatt Foundation is a 501(c)(3) nonprofit organization focused on helping individuals and couples achieve family-building dreams through assisted reproductive technology (ART) by reducing financial barriers to IVF [8][9] - The Conceive Fertility Foundation, founded by Katy Mimari, aims to support individuals affected by infertility through education and grants, with a portion of Caden Lane's profits funding its mission [4][10] - CooperSurgical, a leader in fertility and women's health for nearly 35 years, is dedicated to providing innovative ART and genomic solutions to enhance fertility care [14][15] Program Details - The IVF grant program covers approximately the cost of one IVF cycle, excluding medication fees, with an additional $1,000 towards PGT with ICSI [5] - Grant recipients can choose their clinic, with those within The Prelude Network receiving a 10% discount on fertility services [5][11] - Applications for the grant are open from April 21, 2025, to June 23, 2025, with recipients announced on July 1, 2025 [6]

Core Viewpoint - NewGenIvf Group Limited has secured $5.2 million in strategic funding to support its expansion into the UAE, with plans to establish a fertility clinic in Dubai, leveraging advanced technology and aiming to serve a diverse patient base [1][5][6] Funding Arrangements - The company has entered into two funding arrangements with an investor, with the potential to raise a total of up to $30.8 million [1] - The fourth tranche of debt financing was completed, involving a senior convertible note of $2 million with an interest rate of 14.75% per annum [2] - A new Securities Purchase Agreement was established, allowing for the sale of additional convertible notes not exceeding $25.6 million [3] Expansion Plans - The funding will be utilized to establish a state-of-the-art fertility clinic in Dubai, which will offer a comprehensive suite of services including IVF with gender selection, egg donation, and surrogacy [5] - The clinic aims to attract patients from the UAE, EU countries, and neighboring regions, particularly India, where there is significant demand for fertility services [5] - Construction of the facility is expected to begin in the second quarter of 2025, with an opening targeted for the fourth quarter of the same year [5] Company Background - NewGen is a comprehensive fertility services provider in Asia, with clinics located in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of infertility treatments [7] - The company is dedicated to increasing access to fertility treatments and has a management team with over a decade of experience in the fertility industry [7]